Compare BMR & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMR | NSRX |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | Israel | Israel |
| Employees | N/A | 7 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.1M | 32.2M |
| IPO Year | 2021 | N/A |
| Metric | BMR | NSRX |
|---|---|---|
| Price | $1.83 | $2.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 72.0K | ★ 79.9K |
| Earning Date | 02-26-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $1.98 |
| 52 Week High | $4.32 | $9.99 |
| Indicator | BMR | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 52.99 | 50.24 |
| Support Level | $1.89 | $2.04 |
| Resistance Level | $1.97 | $3.48 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 60.99 | 36.63 |
Beamr Imaging Ltd provides content-adaptive video compression solutions for human viewing and machine vision. The company is trusted by technology companies such as NVIDIA and Amazon Web Services, and serves media companies including Netflix, Paramount, and JioHotstar. Using Emmy-winning patented technology, its solutions help deliver media content with high quality while reducing storage and delivery costs. Its customers include over-the-top content distributors, video streaming platforms, and Hollywood studios that use its products to store, distribute, and monetize video and images across devices. The company operates in the United States, Israel, and the rest of the world, with the United States generating maximum revenue.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.